Terumo Expands Footprint in Organ Transplant Sector with Acquisition of UK-Based OrganOx

Terumo Corporation, a global medical technology company, has acquired Oxford’s OrganOx Limited—an innovator in organ preservation—for $1.5 billion, marking its entry into the organ transplantation market.

OrganOx, founded in 2008 as a spin-out from the University of Oxford by Professors Peter Friend and Constantin Coussios, has developed leading systems in Normothermic Machine Perfusion (NMP). The technology extends the preservation time of donor organs and allows real-time monitoring during transportation, addressing one of the key challenges in transplantation.

Photo by Anna Shvets/Pexels.com

This latest transaction underscores Terumo’s strategic ambition to expand into critical therapeutic areas where next-generation technologies are in high demand. By integrating OrganOx’s expertise, Terumo aims to advance innovations in ex-vivo machine perfusion (EVMP), address pressing challenges in transplantation, and ultimately improve patient survival and quality of life. The company stated that it anticipates the acquisition will enhance its capacity to support healthcare providers in enhancing transplant outcomes and improving patient survival rates.

About Terumo

Founded in Tokyo in 1921, Terumo Corporation is one of the world’s leading medical technology companies, offering products and services across cardiovascular care, hospital solutions, and blood management. With a global presence and a strong focus on research, innovation, and partnerships, Terumo is dedicated to advancing healthcare and enhancing patient outcomes worldwide.

About OrganOx

Headquartered in Oxford, UK, OrganOx Limited is a UK-based medical technology company specializing in normothermic machine perfusion. Its devices are designed to maximize the preservation and function of donor organs before transplantation, helping improve success rates and transform clinical practice.